KRAS Mutation Dynamics in Metastatic Colorectal Cancer

KRAS is a small GTPase oncogene that, when mutated, drives aberrant signalling through the RAS–RAF–MEK–ERK cascade, promoting tumour cell proliferation, survival and metastatic dissemination. Roughly 40–50 % of metastatic colorectal cancers harbour activating KRAS mutations, most frequently at codons 12 and 13, and these alterations have profound implications for prognosis, therapeutic response and disease evolution. Mutant KRAS proteins exist in a constitutively GTP-bound state, evading intrinsic GTPase activity and rendering cells unresponsive to upstream inhibitors of epidermal growth factor receptor. The heterogeneity of KRAS alleles—spanning G12D, G12V, G13D, G12C and others—yields distinct biochemical potencies, differential engagement of downstream effectors and variable patterns of metastatic spread. Dynamic shifts in KRAS subclones under treatment pressure, notably the emergence of secondary mutations that confer resistance to novel allele-specific inhibitors, further complicate clinical management. A nuanced appreciation of these dynamics, integrating tumour sidedness, microsatellite stability, metastatic niche and clonal architecture, is essential to refine precision-medicine strategies and improve patient outcomes on a global scale.

Research from Nature Portfolio

A comprehensive analysis of over 13 000 colorectal tumour samples has revealed distinct KRAS, NRAS and HRAS mutation spectra according to patient age, primary tumour site and microsatellite instability status. Hotspots at codons G12, Q61 and codons beyond exhibit varying transforming capabilities, with certain alleles showing enhanced downstream signalling and poorer clinical prognosis. Structural and functional characterisations of these variants have delineated allele-specific differences in effector binding and GTP hydrolysis rates. Integrative clustering of mutational profiles with transcriptomic subtypes has highlighted co-occurring alterations that may modulate KRAS-driven tumour biology. These insights into the spectrum and context-dependence of RAS mutations underscore the need for allele-tailored therapeutic approaches and inform the development of next-generation inhibitors that accommodate the structural diversity of KRAS oncoproteins.

KRAS Mutation Dynamics in Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in kras mutation dynamics in metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

KRAS: A member of the RAS family of small GTPases; activating point mutations convert it into a constitutively active oncoprotein.

Oncogene: A gene that, when mutated or overexpressed, drives the transformation of a normal cell into a cancer cell.

Metastatic colorectal cancer: Colorectal carcinoma that has spread beyond the primary site to distant organs such as liver, lung or peritoneum.

Microsatellite instability (MSI): A hypermutable phenotype caused by defective DNA mismatch repair, influencing tumour heterogeneity and therapeutic response.

Allele-specific inhibitor: A targeted therapy designed to bind selectively to a particular mutant form of a protein, sparing the wild-type counterpart.

References

1. Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer—A Nation-Wide Study. International Journal of Molecular Sciences (2023).
2. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular Cancer (2021).
3. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nature Communications (2019).
4. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. Journal of Experimental & Clinical Cancer Research (2018).